P M Choi|S R Targan - JoVE Visualize

Showing results (111-120 of 127) with videos related to

Pageof 13

Sort By:

The New England Journal of Medicine|October 9, 1997

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.

Molecular and Cellular Biology|September 1, 1990

Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppressionP M Choi, K M Tchou-Wong, I B Weinstein

Annals of Internal Medicine|September 1, 1991

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter studyC A Sninsky, D H Cort, F Shanahan, et al.

Gut|October 4, 2008

Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activationH Takedatsu, K D Taylor, L Mei, et al.

Gastroenterology|August 7, 2001

CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's diseaseK A Papadakis, J Prehn, S T Moreno, et al.

Gastroenterology|August 1, 1993

Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitisP M Choi, F W Nugent, D J Schoetz, et al.

Digestive Diseases and Sciences|March 1, 1994

Cholangiocarcinoma and Crohn's diseaseP M Choi, F W Nugent, M P Zelig, et al.

Inflammatory Bowel Diseases|August 23, 2001

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.

Gastroenterology|April 21, 2001

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.

Gut|April 11, 2006

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.

Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:

Pageof 13

The New England Journal of Medicine|October 9, 1997

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.

Molecular and Cellular Biology|September 1, 1990

Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppressionP M Choi, K M Tchou-Wong, I B Weinstein

Annals of Internal Medicine|September 1, 1991

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter studyC A Sninsky, D H Cort, F Shanahan, et al.

Gut|October 4, 2008

Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activationH Takedatsu, K D Taylor, L Mei, et al.

Gastroenterology|August 7, 2001

CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's diseaseK A Papadakis, J Prehn, S T Moreno, et al.

Gastroenterology|August 1, 1993

Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitisP M Choi, F W Nugent, D J Schoetz, et al.

Digestive Diseases and Sciences|March 1, 1994

Cholangiocarcinoma and Crohn's diseaseP M Choi, F W Nugent, M P Zelig, et al.

Inflammatory Bowel Diseases|August 23, 2001

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.

Gastroenterology|April 21, 2001

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.

Gut|April 11, 2006

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.

Pageof 13